دورية أكاديمية
DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people.
| العنوان: | DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people. |
|---|---|
| المؤلفون: | Gobran ST; Département de microbiologie, infectiologie, et immunologie, Université de Montréal, Faculté de médicine, Montréal, Québec, Canada.; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada.; Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt., Pagliuzza A; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada., Khedr O; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada., Fert A; Département de microbiologie, infectiologie, et immunologie, Université de Montréal, Faculté de médicine, Montréal, Québec, Canada.; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada., Chomont N; Département de microbiologie, infectiologie, et immunologie, Université de Montréal, Faculté de médicine, Montréal, Québec, Canada.; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada., Bruneau J; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada.; Département de médecine de famille et de médecine d'urgence, Faculté de médecine, Université de Montréal, Montréal, Québec, Canada., Klein MB; Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada.; Department of Medicine, Division of Infectious Diseases, McGill University Health Center (MUHC), Montréal, Québec, Canada., Ancuta P; Département de microbiologie, infectiologie, et immunologie, Université de Montréal, Faculté de médicine, Montréal, Québec, Canada.; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada., Shoukry NH; Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada.; Département de médecine, Faculté de médecine, Université de Montréal, Montréal, Québec, Canada. |
| المصدر: | Journal of virology [J Virol] 2023 Dec 21; Vol. 97 (12), pp. e0110523. Date of Electronic Publication: 2023 Dec 05. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society For Microbiology Country of Publication: United States NLM ID: 0113724 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-5514 (Electronic) Linking ISSN: 0022538X NLM ISO Abbreviation: J Virol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Washington Dc : American Society For Microbiology Original Publication: Baltimore, American Society for Microbiology. |
| مواضيع طبية MeSH: | Antiviral Agents*/pharmacology , Antiviral Agents*/therapeutic use , Coinfection*/drug therapy , Hepatitis C*/complications , Hepatitis C*/drug therapy , Hepatitis C, Chronic*/complications , Hepatitis C, Chronic*/drug therapy , HIV Infections*/complications , HIV Infections*/drug therapy, Humans ; Hepacivirus/physiology ; HIV/physiology |
| مستخلص: | Importance: Antiretroviral therapy (ART) for human immunodeficiency virus (HIV) can control virus replication and prolong the life of people living with HIV (PLWH). However, the virus remains dormant within immune cells in what is called the HIV reservoir. Furthermore, 2.3 million PLWH are also coinfected with hepatitis C virus (HCV) and are at risk of developing chronic liver disease and cancer. HCV treatment with direct acting antivirals (DAA) can completely cure the infection in more than 95% of treated individuals and improve their long-term health outcomes. In this study, we investigated how HCV treatment and cure affect the HIV reservoir. We demonstrate the beneficial impact of DAA treatment as it reduces the HIV reservoirs in particular in people infected with HCV before HIV. These results support the need for early ART and DAA treatment in HIV/HCV coinfections. Competing Interests: The authors declare no conflict of interest. |
| References: | Nat Commun. 2020 Aug 14;11(1):4089. (PMID: 32796830) J Infect Dis. 2018 Jul 13;218(4):624-632. (PMID: 29986086) J Clin Invest. 2020 Feb 3;130(2):998-1009. (PMID: 31697649) J Clin Invest. 2014 Aug;124(8):3352-63. (PMID: 24983321) JCI Insight. 2020 Mar 26;5(6):. (PMID: 32097124) Sci Rep. 2022 Mar 24;12(1):5095. (PMID: 35332180) Hepatol Commun. 2017 Sep;1(7):586-594. (PMID: 29202115) PLoS Comput Biol. 2019 Jul 24;15(7):e1007229. (PMID: 31339888) J Leukoc Biol. 2003 Sep;74(3):360-9. (PMID: 12949239) AIDS. 2015 Mar 27;29(6):675-81. (PMID: 25849831) J Clin Med. 2020 Jul 03;9(7):. (PMID: 32635221) EBioMedicine. 2021 Mar;65:103270. (PMID: 33662832) Curr HIV/AIDS Rep. 2013 Mar;10(1):21-32. (PMID: 23225316) Nat Med. 2016 Sep;22(9):1043-9. (PMID: 27500724) AIDS. 2004 Sep 24;18(14):1951-3. (PMID: 15353981) Retrovirology. 2018 Jan 29;15(1):13. (PMID: 29378657) Sci Transl Med. 2018 Feb 28;10(430):. (PMID: 29491188) Open Forum Infect Dis. 2020 Apr 02;7(5):ofaa115. (PMID: 32391403) Pathog Immun. 2020 Sep 30;5(1):177-239. (PMID: 33089034) Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007096. (PMID: 22229121) PLoS Pathog. 2020 Feb 28;16(2):e1008151. (PMID: 32109259) Dig Dis Sci. 2018 Nov;63(11):2829-2839. (PMID: 30094623) AIDS. 2016 Jan 28;30(3):343-53. (PMID: 26588174) Clin Mol Hepatol. 2018 Sep;24(3):302-310. (PMID: 29526079) Viruses. 2022 Jun 17;14(6):. (PMID: 35746796) J Infect Dis. 2016 Oct 15;214(8):1198-204. (PMID: 27354366) EBioMedicine. 2015 Jun 27;2(8):874-83. (PMID: 26425694) Clin Sci (Lond). 2009 May 14;116(12):861-70. (PMID: 19128241) J Clin Med. 2022 Jun 21;11(13):. (PMID: 35806864) PLoS One. 2017 Mar 21;12(3):e0173943. (PMID: 28323897) Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2307-12. (PMID: 24469825) Open Forum Infect Dis. 2016 May 12;3(2):ofw097. (PMID: 27419169) Front Immunol. 2021 Aug 23;12:723196. (PMID: 34497613) Curr Pharm Des. 2017;23(28):4098-4102. (PMID: 28677507) J Infect Dis. 2016 Dec 15;214(12):1965-1974. (PMID: 27683821) PLoS One. 2017 Oct 27;12(10):e0187095. (PMID: 29077766) HIV Med. 2016 Sep;17(8):581-9. (PMID: 27187749) Nature. 2016 Feb 4;530(7588):51-56. (PMID: 26814962) Nature. 2019 Feb;566(7742):120-125. (PMID: 30700913) Front Immunol. 2021 Aug 12;12:726419. (PMID: 34456931) PLoS One. 2013;8(3):e59302. (PMID: 23555014) Virology. 2006 Jan 20;344(2):283-91. (PMID: 16289657) Antimicrob Agents Chemother. 2020 Aug 20;64(9):. (PMID: 32571815) Med Microbiol Immunol. 2018 Aug;207(3-4):183-194. (PMID: 29523966) J Infect Dis. 2020 Jul 23;222(4):601-610. (PMID: 32201883) Sci Rep. 2019 Apr 3;9(1):5606. (PMID: 30944340) J Virol. 2014 Nov;88(21):12385-96. (PMID: 25122785) J Clin Invest. 2023 Sep 1;133(17):. (PMID: 37463049) Front Med (Lausanne). 2021 Feb 01;8:615342. (PMID: 33598470) |
| معلومات مُعتمدة: | U19 AI159819 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: CD4+ T-cells; HIV viral reservoir; direct acting antivirals; hepatitis C virus |
| المشرفين على المادة: | 0 (Antiviral Agents) |
| تواريخ الأحداث: | Date Created: 20231205 Date Completed: 20240104 Latest Revision: 20240104 |
| رمز التحديث: | 20240104 |
| مُعرف محوري في PubMed: | PMC10734513 |
| DOI: | 10.1128/jvi.01105-23 |
| PMID: | 38051044 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1098-5514 |
|---|---|
| DOI: | 10.1128/jvi.01105-23 |